PULMOCLEAR Sterile Isotonic 0.9% Sodium Chloride - NaCl Inhalation Sterile Saline Solution for Airway Humification – 20 X 2.5 ml Unit Dose Vial, Pharmaceutical Grade

Product Information

For existing patients already receiving supplies from primary care. Repatriation of these patients is not expected. NHS England: Clinical Commissioning Urgent Policy Statement ivacaftor for cystic fibrosis: “off-label” use in patients with named rarer mutations On the other hand, Pulmoclear Isotonic Saline Solution is a sterile Sodium Chloride 0.9% inhalation solution. This solution is specifically formulated for respiratory tract humidification, ensuring optimal moisture levels in the airways. It is suitable for individuals of all ages and can be used to alleviate symptoms of dryness, irritation, and discomfort caused by various respiratory conditions.

Specialist is defined by the APC as a clinician who has undertaken an appropriate formal qualification or recognised training programme within the described area of practice and has a working experience and knowledge within a speciality area Ans : Dizziness, drowsiness, chest tightness, cough, and epigastric tenderness, etc are common side effects. Lybrate is a medium to provide our audience with the common information on medicines and does not guarantee its accuracy or exhaustiveness. Even if there is no mention of a warning for any drug or combination, it never means that we are claiming that the drug or combination is safe for consumption without any proper consultation with an expert. The Pulmocare supplement strengthens respiratory muscles and boosts the energy required for the respiration process AB Phylline N, Broclear tablet, Mucinac AB tablet, Acebcystein tablet and Abiways tablet are some other medicines with a combination of acebrophylline and acetylcysteine. Take this medicine in the exact dose and duration as directed by your doctor. Swallow it as a whole with a glass of water. Do not take more than the prescribed dose. Do not stop taking this medicine on your own.Pulmoclear Tablet shows some common side effects like heartburn, fever, nausea, vomiting, rash, irritation and swelling of the nasal passages (pathway from the nose to throat). Consult your doctor if any of these side effects do not resolve or worsen. Avoid taking this medicine if you are allergic to it. Approved in accordance with NHS England's Clinical Commissioning Policy for licensed and off-label use in patients with cystic fibrosis who have named mutations

For nebulisation (unlicensed use, not recommended) - Use 1-5mL of 20% injection, diluted up to 5ml with normal saline, TDS. (Higher doses less tolerable). Precede with salbutamol as may cause bronchoconstriction. No conclusive proof of efficacy has yet been found.

Patient concerns

Ambroxol theophyllinacetate- Drug Information Portal [Internet]. druginfo.nlm.nih.gov. 2019 [Cited 09 May 2019]. Available from:

Assisted clearance of airway secretions in children and young people where this is complicated by high secretion viscosity. Pulmoclear Syrup is a combination of three medicines. It is used to relieve symptoms of asthma and chronic obstructive pulmonary disease (COPD) such as coughing, wheezing and breathlessness. It helps in relaxing the muscles of the airway, thus widening it and making it easier to breathe. Bronchiectasis: British Thoracic Society Guidelines for the treatment of non-CF bronchiectasis suggest that hypertonic sodium chloridemay be considered for use prior to airway clearance to increasesputum yield, reduce sputum viscosity and improve ease of expectoration (BTS July 2010). The time duration for which this medicine remains effective in the body is subject to variations based on the form of medicine consumed.

Quick tips

Cystic Fibrosis (CF): Delivered following a bronchodilator, hypertonicsodium chloride 7% appears inexpensive and safe with no increasedinfection risk. A Cochrane review stated that there is sufficientevidence to recommend using hypertonic sodium chloride 7% inthose with CF (Wark 2009) (Elkins 2006). In concentrations of 3-14%, hypertonic saline has been shown toimprove tracheobronchial clearance in patients with chronicbronchitis, CF, asthma and normal individuals. Ans : Pulmoclear is a xanthine derivative. It contains Acebrophylline and AcetylCysteine as active ingredients.

This medicine is not recommended for use by pregnant women. Consult your doctor immediately if a pregnancy is suspected while taking this medicine. PULMOCLEAR Inhalation Solution restores sufficient moisture to the mucous membranes of your respiratory passages, preventing the discomfort of them drying out. This supports the natural cleaning process of the respiratory tract, a noticeably positive contribution in cases of inflammation as well as in cases of increased exposure to dust and air pollution (e.g. caused by dust or tobacco smoke). A supporting prescribing guideline may be requested which must have been agreed by the relevant secondary care trust DTCs and approved by the Nottinghamshire APC. Both Pulmoclear Hypertonic and Pulmoclear Isotonic Inhalation Solutions are recommended to be used with a nebulizer. The nebulizer effectively converts the solution into a fine mist that can be inhaled, allowing for targeted delivery deep into the lungs. This delivery method ensures maximum efficacy and fast relief. Pulmoclear Inhation Solution available in different strengths: Grey / Non-Formulary (no formal assessment): APC has not formally reviewed this medicine or indication because it had never been requested for formulary inclusion. Often used for drugs new to market.The Pulmocare powder reduces the production of diet-induced carbon dioxide to improve breathing and fight breathlessness PULMOCLEAR Inhalation Solution is not subject to any age limit restrictions and may therefore also be administered to small children. Approved in accordance with NHS England ClinicalCommissioning UrgentPolicy Statementsfor the treatment ofcystic fibrosis in patients 6 years and older with named mutations. Usedin combination with ivacaftor. Also available at NUH for non-CF paediatric patients for short term in-patient use on consultantrecommendation only. The supporting prescribing guideline must have been agreed by the relevant secondary care trust D&TC(s) and approved by the Nottinghamshire APC.